1.	Stem Cell Transplant for Hematological Malignancy Phase: Phase III Type: Treatment Status: Active Age: 54 and under Sponsor: Other Protocol IDs: 0107M05202, MT2001-02, NCT00176930
2.	Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Phase: Phase III Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: SCT 0307, NCT00619879
3.	Chemotherapy Followed by Allogeneic Stem Cell Transplantation in Treating Children With Hematologic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 4 to 21 Sponsor: NCI Protocol IDs: NCI-01-C-0125F, NCT00020592
4.	Stem Cell Transplant for Hematologic Diseases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 8713-HIMSUM, NCT00058825
5.	Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant Phase: Phase II, Phase I Type: Treatment Status: Active Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1825.00, NCI-2010-00230, P01CA078902, FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
6.	Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and under Sponsor: Other Protocol IDs: 1999LS073, MT1999-20, 9911M24961, NCT00167219
7.	Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease Phase: Phase II, Phase I Type: Treatment Status: Active Age: Under 55 Sponsor: NCI, Other Protocol IDs: 06-125, MSKCC-06125, NCT00423514
8.	Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
9.	Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: Any age Sponsor: NCI, Other Protocol IDs: 2230.00, NCI-2010-00106, P01CA078902, FHCRC-2230.00, IR-6771, NCT00789776
10.	Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 6 montha to 70 Sponsor: Other Protocol IDs: J1055, NA_00039823, NCT01203722
11.	To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 20 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 100220, IND 59,056, NCT01222780
12.	Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Active Age: 6 months to 85 Sponsor: Other Protocol IDs: J1151, NA_00048378, NCT01342289
13.	Improving Blood Stem Cell Collection and Transplant Procedures Phase: Phase II, Phase I Type: Treatment Status: Active Age: 3 to 79 Sponsor: NHLBI Protocol IDs: 120028, 12-H-0028, NCT01517035
14.	Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow Phase: Phase II Type: Treatment Status: Active Age: 8 to 80 Sponsor: NHLBI Protocol IDs: 990050, 99-H-0050, NHLBI-99-H-0050, NCT00003838
15.	Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 65 and under Sponsor: NCI Protocol IDs: CPMC-IRB-AAAA5571, CPMC-CAMP-016, NCI-G00-1891, NCT00008216
16.	Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: PSCI-2003-232, NCT00084695
17.	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant For Hematologic Cancer Phase: Phase II Type: Supportive care, Treatment Status: Active Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1898.00, NCI-2010-00267, P01HL036444, P01CA078902, FHCRC-1898.00, 5788, NCT00089011
18.	Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer Phase: Phase II Type: Treatment Status: Active Age: 45 and under Sponsor: Other Protocol IDs: 2005LS043, UMN-MT2005-10, UMN-0507M71475, UMN-2005LS043, UMN-BMT-MT2005-10, NCT00309842
19.	Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC]) Phase: Phase II Type: Treatment Status: Active Age: 18 and under Sponsor: Other Protocol IDs: BMT 0300 Mini, NCT00179764
20.	Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By an Umbilical Cord Blood Transplant, Sirolimus, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer Phase: Phase II Type: Treatment Status: Active Age: Under 70 Sponsor: Other Protocol IDs: 2005LS036, UMN-MT-2005-02, UMN-0507M70121, UMN-2005LS036, NCT00305682
21.	TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD Phase: Phase II Type: Treatment Status: Active Age: 0 to 75 Sponsor: NCI, Other Protocol IDs: BMT168, 95130, 13680, NCT00185796
22.	Cyclophosphamide, Fludarabine, Total-Body Irradiation, and Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer or Other Disease Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 4 to 50 Sponsor: Other Protocol IDs: CDR0000502363, MSKCC-06014, NCT00388102
23.	Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: H-20971-IL2 for GvHD, IL-2 for GVHD, NCT00539695
24.	Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies Phase: Phase II Type: Treatment Status: Active Age: 2 to 21 Sponsor: Other Protocol IDs: HIFLEX, NCT00566696
25.	Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2007LS072, UMN-MT2007-07, 0707M11845, UMN-2007LS072, NCT00617929